Broadfin Capital, LLC, 10% Owner at PROGENICS PHARMACEUTICALS INC (PGNX), sold 805,200 shares at $9.70 ($7.8M) on 2017-02-13, disclosed to the SEC on 2017-02-15.
Open-market sale of $7.8M PGNX by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.70 | 100,000 | $970K | 12.5% |
| 2 | $9.70 | 100,000 | $970K | 12.5% |
| 3 | $9.68 | 150,000 | $1.5M | 18.7% |
| 4 | $9.70 | 52,600 | $510K | 6.6% |
| 5 | $9.70 | 100,000 | $970K | 12.5% |
| 6 | $9.70 | 52,600 |
| $510K |
| 6.6% |
| 7 | $9.70 | 50,000 | $485K | 6.2% |
| 8 | $9.70 | 50,000 | $485K | 6.2% |
| 9 | $9.55 | 150,000 | $1.4M | 18.4% |
| Total | $9.67 avg | 805,200 | $7.8M | 100% |
| Filing → |
| BDSI | SELL | 2019-05-14 | $9.0M | — | Filing → |
| REPH | SELL | 2018-05-24 | $1.1M | — | Filing → |
| REPH | SELL | 2018-03-15 | $2.0M | — | Filing → |